Luteolin inhibits proliferation of MKN45 and SGC7901 gastric cancer cells. a: Western blot analysis of cMet expression in a series of gastric cancer cell lines, including MKN45, MKN28, AGS, BGC823 and SGC7901 cells. b: Assessment of cell proliferation and viability, using the MTT assay, in MKN45 and SGC7901 cells treated with varying concentrations of luteolin (10–80 μM) or DMSO (1 μL/mL) for 24, 48 or 72 h. c: Evaluation of cell apoptosis, using flow cytometry and propidium iodide/annexin-V staining, in MKN45 and SGC7901 cells treated with varying concentrations of luteolin (10–80 μM) or DMSO (1 μL/mL) for 24 h. The gate setting distinguished between early apoptotic (bottom right), late apoptotic (top right), living (bottom left) and necrotic (top left) cells. d: The percentage of total apoptotic MKN45 and SGC7901 cells for varying concentrations of luteolin (20–80 μM) or DMSO (1 μL/mL), quantified from three independent experiments. e: Western blot analysis of cleaved caspase-3 and cleaved PARP expression after treatment with luteolin for 24 h. Data are presented as the mean ± SD. The blots shown are representative of those from at least three independent experiments.